Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Abroad (travel likely)RecruitingPHASE2

Conditions

Cutaneous T Cell Lymphoma · Fungoides Mycosis Sezary Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Contact: Study coordinator (Ryan Wilcox, M.D.) · rywilcox@umich.edu · 734-615-1482
Contact: Principal Investigator (Jonathon Weiss, M.D.)

Study leads

Ryan Wilcox
Principal Investigator
University of Michigan Rogel Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Sezary Syndrome · Mycosis Fungoides

Abroad (travel likely)RecruitingPHASE2

Stanford, United States

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Folliculotropic Mycosis Fungoides · Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Sezary Syndrome

Abroad (travel likely)RecruitingPHASE2

Scottsdale, United States · Duarte, United States

Photopheresis in Early-stage Mycosis Fungoides

Cutaneous T Cell Lymphoma · Mycosis Fungoides

Abroad (travel likely)RecruitingPHASE2

New York, United States

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell Lymphoma · Graft Versus Host Disease · Lymphoma, T-Cell

Abroad (travel likely)RecruitingPHASE2

Columbus, United States